Outcomes of Infants Born to Women Infected With Hepatitis B
Outcomes of Infants Born to Women Infected With Hepatitis B
复制标题
DOI：
10.1542/peds.2014-3213
复制
发表时间：
2015-05-01
期刊：
影响因子：
8
通讯作者：
Murphy, Trudy V.
中科院分区：
文献类型：
--
作者：
Schillie, Sarah;Walker, Tanja;Murphy, Trudy V.
背景和目的：围产期暴露是B型肝炎病毒（HBV）传播的一种重要方式，导致约90%的感染婴儿出现慢性疾病。推荐给B型肝炎表面抗原阳性母亲所生婴儿的免疫预防可减少高达95%的围产期HBV感染。我们试图找出与围产期HBV transmission.METHODS相关的因素：我们分析了2007-2013年期间从美国资助的64个围产期B肝炎预防项目中的5个项目前瞻性收集的数据。我们研究了产妇的人口统计学和实验室检查结果，婴儿胎龄和出生体重，免疫预防管理对围生期HBV感染的影响。在9252例（51.5%）婴儿的B型肝炎表面抗原检测结果，100例（1.1%）获得围产期HBV感染。在11335名有信息的婴儿中，10760名（94.9%）在出生后12小时内接种了B肝炎（HepB）疫苗和B肝炎免疫球蛋白。围产期HBV感染与母亲年龄较小（P = .01）、亚洲/太平洋岛民（P < .01）、母亲B肝炎e抗原阳性（P <.01）、母亲B肝炎e抗原抗体阴性（P <.01）、母亲病毒载量>= 2000 IU/mL（P = .04）和婴儿接受
BACKGROUND AND OBJECTIVES: Perinatal exposure is an important mode of hepatitis B virus (HBV) transmission, resulting in chronic disease in similar to 90% of infected infants. Immunoprophylaxis recommended for infants born to hepatitis B surface antigen-positive mothers reduces up to 95% of perinatal HBV infections. We sought to identify factors associated with perinatal HBV transmission.METHODS: We analyzed prospectively collected data from 5 of 64 US-funded Perinatal Hepatitis B Prevention Programs during 2007-2013. We examined effects of maternal demographic and laboratory results, infant gestational age and birth weight, and immunoprophylactic management on perinatal HBV infection.RESULTS: Data from 17 951 mother-infant pairs were analyzed. Among 9252 (51.5%) infants for whom hepatitis B surface antigen testing results were available, 100 (1.1%) acquired perinatal HBV infection. Both hepatitis B (HepB) vaccine and hepatitis B immune globulin were administered within 12 hours of birth for 10 760 (94.9%) of 11 335 infants with information. Perinatal HBV infection was associated with younger maternal age (P = .01), Asian/Pacific Islander race (P < .01), maternal hepatitis B e-antigen positivity (P < .01), maternal antibody to hepatitis B e-antigen negativity (P < .01), maternal viral load >= 2000 IU/mL (P = .04), and infant receipt of